Although FGF23, SSTR2A, and NSE are not specific for PMTs,[20–22] the combination of these immunophenotypes (FGF23+, SSTR2A+, and NSE+) rules out other tumors, including solitary fibrous tumor/hemangiopericytoma, synovial sarcomas, and schwannomas. This evidence concerns the gene ENO2 and schwannoma.